Lin A - Search Results

1

DNAH10 mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer.

Li M, Lin A, Luo P, Shen W, Xiao D, Gou L, Zhang J, Guo L. Li M, et al. Among authors: lin a. Aging (Albany NY). 2020 Jan 20;12(2):1285-1303. doi: 10.18632/aging.102683. Epub 2020 Jan 20. Aging (Albany NY). 2020. PMID: 31959735 Free PMC article.

2

The efficacy of the new medical internship management network system.

Xia O, Ye J, Lin A, Chen Y, Guo W, Fong T, Qian R, Luo P, Zeng Z. Xia O, et al. Among authors: lin a. Medicine (Baltimore). 2019 Feb;98(7):e14435. doi: 10.1097/MD.0000000000014435. Medicine (Baltimore). 2019. PMID: 30762751 Free PMC article.

3

A novel mutation panel for predicting etoposide resistance in small-cell lung cancer.

Qiu Z, Lin A, Li K, Lin W, Wang Q, Wei T, Zhu W, Luo P, Zhang J. Qiu Z, et al. Among authors: lin a, lin w. Drug Des Devel Ther. 2019 Jun 21;13:2021-2041. doi: 10.2147/DDDT.S205633. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31417239 Free PMC article.

4

Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.

Lin A, Wei T, Meng H, Luo P, Zhang J. Lin A, et al. Mol Cancer. 2019 Sep 16;18(1):139. doi: 10.1186/s12943-019-1062-7. Mol Cancer. 2019. PMID: 31526368 Free PMC article. Review.

5

Association between Circulating Inflammatory Proteins and Clinical Prognosis in Chinese Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer.

Guan R, Lin A, Luo P, Zhang J. Guan R, et al. Among authors: lin a. J Thorac Oncol. 2019 Oct;14(10):e222-e224. doi: 10.1016/j.jtho.2019.05.027. J Thorac Oncol. 2019. PMID: 31558232 Free article. No abstract available.

6

DDR Pathway Alteration, Tumor Mutation Burden, and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole Exome and Targeted Gene Sequencing.

Luo P, Lin A, Li K, Wei T, Zhang J. Luo P, et al. Among authors: lin a. J Thorac Oncol. 2019 Dec;14(12):e276-e279. doi: 10.1016/j.jtho.2019.08.2509. J Thorac Oncol. 2019. PMID: 31757380 Free article. No abstract available.

7

Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.

Lin A, Zhang H, Hu X, Chen X, Wu G, Luo P, Zhang J. Lin A, et al. Pharmacol Res. 2020 Sep;159:105028. doi: 10.1016/j.phrs.2020.105028. Epub 2020 Jun 20. Pharmacol Res. 2020. PMID: 32569820

8

ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer.

Zhang J, Zhou N, Lin A, Luo P, Chen X, Deng H, Kang S, Guo L, Zhu W, Zhang J. Zhang J, et al. Among authors: lin a. Cancer Immunol Immunother. 2021 Jan;70(1):137-151. doi: 10.1007/s00262-020-02668-8. Epub 2020 Jul 11. Cancer Immunol Immunother. 2021. PMID: 32653938 Free PMC article.

9

Characterization of aberrant pathways activation and immune microenviroment of BK virus associated nephropathy.

Liu Y, Zhou S, Hu J, Xu W, Liu D, Liao J, Liao G, Guo Z, Li Y, Yang S, Li S, Chen H, Guo Y, Li M, Fan L, Li L, Lin A, Zhao M. Liu Y, et al. Among authors: lin a. Aging (Albany NY). 2020 Jul 13;12(14):14434-14451. doi: 10.18632/aging.103486. Epub 2020 Jul 13. Aging (Albany NY). 2020. PMID: 32668411 Free PMC article.

10

EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma.

Huang W, Lin A, Luo P, Liu Y, Xu W, Zhu W, Wei T, Lyu Q, Guo L, Zhang J. Huang W, et al. Among authors: lin a. Cancer Gene Ther. 2021 Aug;28(7-8):864-874. doi: 10.1038/s41417-020-0207-6. Epub 2020 Aug 6. Cancer Gene Ther. 2021. PMID: 32759987

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,025 results

Search Page

Filters